Difference between revisions of "Aminoglutethimide (Cytadren)"
m |
|||
| Line 18: | Line 18: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Endocrine therapy]] | ||
[[Category:Steroid synthesis inhibitors]] | [[Category:Steroid synthesis inhibitors]] | ||
[[Category:Aromatase inhibitors]] | [[Category:Aromatase inhibitors]] | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
| + | [[Category:Drugs FDA approved in 1980]] | ||
Revision as of 21:11, 5 November 2014
This medication is no longer commercially available
General information
Class/mechanism: Inhibitor of adrenalcortical steroid synthesis, blocks conversion of cholesterol to pregnenolone and subsequent synthesis of adrenal steroids, has aromatase inhibitor activity.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]